New eczema drug shows promise in Mid-Stage trial

NCT ID NCT07037901

Recruiting now Disease control Sponsor: Inmagene LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study tests whether IMG-007 can safely reduce eczema symptoms like itching and redness in adults with moderate-to-severe disease who haven't responded well to topical treatments. About 405 participants will receive either the drug or a placebo, and researchers will measure skin improvement over 24 weeks. The goal is to find the best dose for controlling this chronic skin condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema immune system disorder skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ATOPIC DERMATITIS ECZEMA ECZEMA

Contacts and locations

Locations

Inmagene Site 1
RECRUITING

Lancaster, California, 93534, United States
Inmagene Site 10
RECRUITING

Fargo, North Dakota, 58103, United States
Inmagene Site 11
RECRUITING

Woodbury, New York, 11797, United States
Inmagene Site 12
RECRUITING

Anderson, South Carolina, 29621, United States
Inmagene Site 13
RECRUITING

Mississauga, Ontario, L4Y 4C5, Canada
Inmagene Site 14
RECRUITING

Montreal, Quebec, H2X 2V1, Canada
Inmagene Site 15
RECRUITING

Surrey, British Columbia, V3R 6A7, Canada
Inmagene Site 16
RECRUITING

Saskatoon, Saskatchewan, S7K 2C1, Canada
Inmagene Site 17
RECRUITING

Greater Sudbury, Ontario, P3C 1X8, Canada
Inmagene Site 18
RECRUITING

North Bay, Ontario, P1B 3Z7, Canada
Inmagene Site 19
RECRUITING

Ocala, Florida, 34470, United States
Inmagene Site 2
RECRUITING

Rolling Meadows, Illinois, 60008, United States
Inmagene Site 20
RECRUITING

Charlotte, North Carolina, 28277, United States
Inmagene Site 21
RECRUITING

New York, New York, 10029, United States
Inmagene Site 22
RECRUITING

Vancouver, British Columbia, V6H 4B1, Canada
Inmagene Site 23
RECRUITING

Los Angeles, California, 90095, United States
Inmagene Site 24
NOT_YET_RECRUITING

Mitcham, Victoria, 3132, Australia
Inmagene Site 25
NOT_YET_RECRUITING

Woden, Australian Capital Territory, 2606, Australia
Inmagene Site 26
NOT_YET_RECRUITING

Benowa, Queensland, 4217, Australia
Inmagene Site 27
NOT_YET_RECRUITING

Carlton, Victoria, 3053, Australia
Inmagene Site 28
NOT_YET_RECRUITING

Liverpool, New South Wales, 2170, Australia
Inmagene Site 29
NOT_YET_RECRUITING

Hamilton, Waikato Region, 3204, New Zealand
Inmagene Site 3
RECRUITING

Portland, Oregon, 97210, United States
Inmagene Site 30
NOT_YET_RECRUITING

Auckland, 1051, New Zealand
Inmagene Site 4
RECRUITING

Tampa, Florida, 33609, United States
Inmagene Site 5
RECRUITING

Mayfield Heights, Ohio, 44124, United States
Inmagene Site 6
RECRUITING

Kew Gardens, New York, 11415, United States
Inmagene Site 7
RECRUITING

Burien, Washington, 698168, United States
Inmagene Site 8
RECRUITING

Southlake, Texas, 76092, United States
Inmagene Site 9
RECRUITING

Columbus, Ohio, 43213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.